January 7, 2021

Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing

—  Proceeds support advancement of Precision Oncology 2.0 drug-hunting engine and first wave of therapeutic candidates — — Company management to present at 39th Annual J.P....

October 26, 2020

Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0

— Company building comprehensive drug hunting engine to broaden the reach and impact of precision medicine for oncology — — Industry veteran and experienced drug developer...


Fierce Biotech   |   January 12, 2021

Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.

Boston Globe   |   January 12, 2021

Just over two months after announcing its debut with $108 million in funding, Boston startup Scorpion Therapeutics said Thursday it has raised an even larger amount of venture capital.

Endpoints News   |   January 12, 2021

Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.

Fierce Biotech   |   October 26, 2020

When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.”

Boston Globe   |   October 26, 2020

Gary Glick is chief executive of Scorpion Therapeutics. Courtesy of Scorpion Therapeutics.  Scorpion Therapeutics is the latest biotech to debut in Boston, with $108 million in venture capital and a roster of local industry veterans.

Endpoints News   |   October 26, 2020

Just weeks before the pandemic hit the states, Gary Glick and Keith Flaherty had a chance to spend 12 hours together, talking craft and trade on...


J.P. Morgan 39th Annual Healthcare Conference   |   January 13, 2021

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.

Media Contact
Jackie Byrne
Ten Bridge Communications

Contact Us